Dotted Core-Shell Nanoparticles for T₁ -Weighted MRI of Tumors.

ABSTRACT: Gd-based T ₁ -weighted contrast agents have dominated the magnetic resonance imaging (MRI) contrast agent market for decades. Nevertheless, they are reported to be nephrotoxic and the U.S. Food and Drug Administration has issued a general warning concerning their use. In order to reduce the risk of nephrotoxicity, the MRI performance of the Gd-based T ₁ -weighted contrast agents needs to be improved to allow a much lower dosage. In this study, novel dotted core-shell nanoparticles (FeGd-HN3-RGD2) with superhigh r ₁ value (70.0 mM^-1 s^-1 ) and very low r ₂ /r ₁ ratio (1.98) are developed for high-contrast T ₁ -weighted MRI of tumors. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

SUBMITTER: Shen Z 

PROVIDER: S-EPMC6320323 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature